Glytec’s solutions return millions of dollars to hospitals and health systems by improving outcomes for insulin-requiring patients.
Every day, one of three hospitalized patients receives insulin therapy during their stay and more than eight million people living with diabetes rely on insulin therapy to control their blood glucose.
Although widely prescribed and absolutely necessary, insulin is inherently dangerous. Fifty percent of all medication errors involve insulin, including one-third of all fatal medication errors. Insulin is considered a high-alert medication because it has the potential to cause significant patient harm if misused.1-31 Institute for Safe Medication Practices. High-Alert Medications in Acute Care Settings. July 2014. https://www.ismp.org/recommendations/high-alert-medications-acute-list2 Cousins D, Rosario C, Scarpello J. Insulin, hospitals and harm: a review of patient safety incidents reported to the National Patient Safety Agency. Clin Med (Lond). 2011 Feb;11(1):28-30.3 The United States Pharmacopeial Convention, National Coordinating Council for Medication Error Reporting and Prevention. Institute for Safe Medication Practices Medication Errors Reporting Program.
Improper insulin management can have potentially catastrophic consequences, including as coma, kidney failure, stroke, paralysis, sepsis, brain damage, cardiac arrest and death.4-254 Umpierrez GE, et al. Management of hyperglycemia in hospitalized patients in non-critical care setting: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012 Jan;97(1):16-38.5 The ACE/ADA Task Force on Inpatient Diabetes. American College of Endocrinology and American Diabetes Association consensus statement on inpatient diabetes and glycemic control: a call to action. Diabetes Care. 2006 Aug;29(8):1955-62. Endocr Pract. 2006 Jul-Aug;12(4):458-68.6 Braithwaite SS, et al. Hospital hypoglycemia: not only treatment but also prevention. Endocr Pract. 2004 Mar-Apr;10 Suppl 2:89-99.7 Moghissi ES, et al. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care. 2009 Jun;32(6):1119-31. Endocr Pract. 2009 May-Jun;15(4):353-69.8 Institute for Safe Medication Practices. Guidelines for optimizing safe subcutaneous insulin use in adults. 2017.9 Hellman R. Patient safety and inpatient glycemic control: translating concepts into action. Endocr Pract. 2006 Jul-Aug;12 Suppl 3:49-55.10 Hellman R. A systems approach to reducing errors in insulin therapy in the inpatient setting. Endocr Pract. 2004 Mar-Apr;10 Suppl 2:100-8.11 Pennsylvania Patient Safety Authority. Medication errors with the dosing of insulin: problems across the continuum. Pa Patient Saf Advis 2010 Mar;7(1):9-17.12 Amori RE, et al. Inpatient medical errors involving glucose-lowering medications and their impact on patients: review of 2,598 incidents from a voluntary electronic error reporting database. Endocr Pract. 2008 Jul-Aug;14(5):535-42.13 Classen DC, Jaser L, Budnitz DS. Adverse drug events among hospitalized Medicare patients: epidemiology and national estimates from a new approach to surveillance. Jt Comm J Qual Patient Saf. 2010 Jan;36(1):12-21.14 Varghese P, Gleason V, Sorokin R, Senholzi C, Jabbour S, Gottlieb JE. Hypoglycemia in hospitalized patients treated with antihyperglycemic agents. J Hosp Med. 2007 Jul;2(4):234-40.15 Smith WD, Winterstein AG, Johns T, Rosenberg E, Sauer BC. Causes of hyperglycemia and hypoglycemia in adult inpatients. Am J Health Syst Pharm. 2005 Apr 1;62(7):714-9.16 Winterstein AG, Hatton RC, Gonzalez-Rothi R, Johns TE, Segal R. Identifying clinically significant preventable adverse drug events through a hospital’s database of adverse drug reaction reports. Am J Health Syst Pharm. 2002 Sep 15;59(18):1742-9.17 Cousins D, Rosario C, Scarpello J. Insulin, hospitals and harm: a review of patient safety incidents reported to the National Patient Safety Agency. Clin Med (Lond). 2011 Feb;11(1):28-30.18 Garrouste-Orgeas M, et al. Selected medical errors in the intensive care unit: results of the IATROREF study: parts I and II. Am J Respir Crit Care Med. 2010 Jan 15;181(2):134-42.19 Cornish W. Safe and appropriate use of insulin and other antihyperglycemic agents in hospital. Can J Diabetes. 2014 Apr;38(2):94-100.20 Spector WD, Limcangco R, Furukawa MF, Encinosa WE. The marginal costs of adverse drug events associated with exposures to anticoagulants and hypoglycemic agents during hospitalization. Med Care. 2017 Sep;55(9):856-863.21 Cryer PE. Death during intensive glycemic therapy of diabetes: mechanisms and implications. Am J Med. 2011 Nov;124(11):993-6.22 Cohen MR. Pharmacists’ role in ensuring safe and effective hospital use of insulin. Am J Health Syst Pharm. 2010 Aug;67(16 Suppl 8):S17-21.23 Alrwisan A, Ross J, Williams D. Medication incidents reported to an online incident reporting system. Eur J Clin Pharmacol. 2011 May;67(5):527-32.24 Thomas AN, Panchagnula U. Medication-related patient safety incidents in critical care: a review of reports to the UK National Patient Safety Agency. Anaesthesia. 2008 Jul;63(7):726-33.25 Schwenk ES, Mraovic B, Maxwell RP, Kim GS, Ehrenfeld JM, Epstein RH. Root causes of intraoperative hypoglycemia: a case series. J Clin Anesth. 2012 Dec;24(8):625-30.
The combination of Glytec’s eGlycemic Management System® and expert professional services help you achieve best practices in glycemic management across all service lines, settings and transitions of care — inpatient, outpatient and virtual alike — creating the standardization, personalization and workflow efficiencies that drive costs down and ensure your clinical teams are equipped to provide the safest, highest quality care to your patients.
Our solutions have served to reduce severe hypoglycemia by as much as 99.8%, 30-day readmissions by 36% to 68% and lengths of stay by up to 3.2 days, leading to overall cost savings as high as $20,000 per licensed bed.
Intensive Care Unit